Another example of mutation in SMARCA4 that has been associated with an increased risk for developing a malignant type of soft tissue tumor called rhabdoid tumor is that germline heterozygous loss-of-function mutations in SMARCA4 (19q13.2) cause rhabdoid tumor predisposition syndrome II. This evidence concerns the gene SMARCA4 and soft tissue neoplasm.